[HTML][HTML] Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
W Lewis, IL Grupp, G Grupp, B Hoit, R Morris… - Laboratory …, 2000 - Elsevier
Cardiomyopathy in AIDS is an increasingly important clinical problem. Mechanisms of AIDS
cardiomyopathy were explored using AIDS transgenic mice that express replication-
incompetent HIV-1 (NL4–3Δ gag/pol). Transgenic and FVB/n mice (n= 3 to 6 per cohort)
received water ad libitum with and without zidovudine (3′-azido-2′, 3′-deoxythymidine;
AZT; 0.7 mg/ml) for 21 or 35 days. After 21 days, echocardiographic studies were performed
and abundance of mRNA for cardiac sarcoplasmic reticulum calcium ATPase (SERCA2) …
cardiomyopathy were explored using AIDS transgenic mice that express replication-
incompetent HIV-1 (NL4–3Δ gag/pol). Transgenic and FVB/n mice (n= 3 to 6 per cohort)
received water ad libitum with and without zidovudine (3′-azido-2′, 3′-deoxythymidine;
AZT; 0.7 mg/ml) for 21 or 35 days. After 21 days, echocardiographic studies were performed
and abundance of mRNA for cardiac sarcoplasmic reticulum calcium ATPase (SERCA2) …